Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort studyBelén Gutiérrez‐Gutiérrez, Mario Fernández‐Ruiz, Εlias Iosifidis et al.|The Lancet Infectious Diseases|2017Cited by 521
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort studyMinggui Wang, H. R. Cross, Michelle Earley et al.|The Lancet Infectious Diseases|2021Cited by 338
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort studyDavid van Duin, Robert A. Bonomo, César A. Arias et al.|The Lancet Infectious Diseases|2020Cited by 328
Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by<i>Enterobacter</i>,<i>Citrobacter</i>or<i>Serratia</i>species: a systematic review with meta-analysisPatrick N. A. Harris, David L. Paterson, Jane Y. Wei et al.|Journal of Antimicrobial Chemotherapy|2015Cited by 86
Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definitionPatrick N. A. Harris, David L. Paterson, John F. McNamara et al.|Clinical Microbiology and Infection|2016Cited by 83